Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 4 analysts offering 12 month price targets for Evotec SE (ADR) have a median target of 5.90, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a 10.28% increase from the last price of 5.35.
High86.9%10.00
Med10.3%5.90
Low-43.9%3.00

Earnings history & estimates in USD

On Nov 06, 2024, Evotec SE (ADR) reported 3rd quarter 2024 losses of -0.121 per share.
Average growth rate-66.17%
Evotec SE (ADR) reported annual 2023 losses of -0.2540 per share on Apr 24, 2024.
Average growth rate+51.15%
More ▼

Revenue history & estimates in USD

Evotec (US), Inc. had 3rd quarter 2024 revenues of 203.10m. This missed the 210.97m consensus estimate of the 2 analysts following the company. This was 11.36% below the prior year's 3rd quarter results.
Average growth rate-0.95%
Evotec (US), Inc. had revenues for the full year 2023 of 844.85m. This was 7.03% above the prior year's results.
Average growth rate+7.55%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.